Introducing Parallel Search Turbo: the fastest and lowest-cost search for AI

HumanMachine

Life Sciences

Track every drug, regulation, and competitor in your space

Track every drug, trial, regulation, and competitor automatically, with structured, cited intelligence pulled from registries and filings in real time.

Monitor clinical trial registries and FDA updates for my target and indication.

• New Phase 2 trial posted for a GLP-1 analog
  clinicaltrials.gov
  5M AGO
• FDA grants Fast Track to a KRAS inhibitor
  fda.gov
  1H AGO
• Competitor reports positive Phase 3 topline
  businesswire.com
  5H AGO

Use Cases

Research the whole drug landscape

Map, monitor, and mine the science behind every decision

Map a drug or target's competitive landscape

Give it a therapeutic area, target, or mechanism. Get back approved and investigational assets, the companies behind them, clinical status, and the investors active in the space, as a structured, cited output.

Map the KRAS G12D inhibitor landscape: assets, the companies behind them, and clinic status.

Monitor pipelines, trials, and approvals

Watch the drugs, programs, and competitors you care about: trial readouts, phase transitions, FDA and EMA approvals, guidance, and commercialization events, with alerts the moment something material changes.

Watch NVX-301 and the KRAS G12D set: trial readouts, phase transitions, and FDA/EMA approvals.

Mine scientific literature and clinical data

Pull clean, structured data out of papers, trial registries, and regulatory filings, including efficacy, mechanism of action, endpoints, and real-world evidence.

CLINICAL DATA

• NVX-301 · Phase 2
• MECHANISM: KRAS G12D inhibitor
• INDICATION: Metastatic colorectal cancer
• ENROLLMENT: 248
• PRIMARY ENDPOINT: ORR 41% (95% CI 34–48)

Discover licensing and M&A targets

Describe your criteria in plain language and get back a live list of assets or companies, including the long tail of private biotechs that never make it onto traditional databases.

Customer Stories

Formation Bio runs its drug-development funnel on Parallel

Formation Bio monitors tens of thousands of drug programs daily, auto-enriches the ones that matter, and commissions deep research on priority assets to inform valuation.

Convoke mines the biopharma literature at research-grade precision

The biopharma AI company runs deep research and monitoring over scientific publications, trials, and regulatory sources – Work that demands exact publication dates and traceable citations.

"Parallel provided us with a big upgrade in speed and index coverage. Combined with a 5x improvement in cost efficiency, it was an easy decision to build our agents with them."

Vikas Velagapudi, Founder, Convoke

Trust

Built for enterprise, secure by design

Every Parallel output includes the Basis framework, unique to Parallel: calibrated confidence scores, citations, source excerpts, and reasoning traces.

• SOC 2 Type 2
• Zero data retention Available
• HIPAA-ready offering
• GDPR Compliance
• Single sign-on (SSO/SAML)

FAQs

• Can Parallel monitor clinical trial registries automatically? Yes. The Monitor API watches ClinicalTrials.gov, FDA, and EMA sources for phase transitions, readouts, and approvals — alerting the moment something material changes on the drugs and programs you care about.

• How does Parallel help map a drug's competitive landscape? Give Parallel a therapeutic area, target, or mechanism. FindAll and Task return approved and investigational assets, the companies behind them, clinical status, and active investors — as a structured, cited output.

• Does Parallel cover FDA and EMA regulatory data? Yes. Parallel reads regulatory filings and announcements continuously, including FDA Fast Track designations and EMA CHMP opinions, alongside trial registries and scientific literature — with citations on every claim.

• Can I use Parallel for biotech licensing or M&A target discovery? Yes. Describe your criteria in plain language and FindAll returns a live list of assets or companies — including the long tail of private, clinical-stage biotechs that never appear on traditional databases.